Navidea biopharmaceuticals reports first quarter 2021 financial results

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter for the period ended march 31, 2021. “we are continuing a positive dialogue with the fda and are moving as quickly as we can to fully document all the data from arm 3 of nav3-31,” said mr. jed a. latkin, chief executive offic
NAVB Ratings Summary
NAVB Quant Ranking